



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

03104954.7

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office  
Le Président de l'Office européen des brevets  
p.o.

R C van Dijk

BEST AVAILABLE COPY



Anmeldung Nr:  
Application no.: 03104954.7  
Demande no:

Anmeldetag:  
Date of filing: 23.12.03  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Akzo Nobel N.V.  
Velperweg 76  
6824 BM Arnhem  
PAYS-BAS

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se referer à la description.)

COMBINATION VACCINE FOR POULTRY

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

A61K39/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignés lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL  
PT RO SE SI SK TR LI

## Combination vaccine for poultry

The present invention relates to a combination vaccine for the protection of poultry against *Ornithobacterium rhinotracheale*, to the use of a live over-attenuated *Ornithobacterium rhinotracheale* strain and a live attenuated poultry virus for the manufacturing of such a combination vaccine, to methods for the preparation of said combination vaccine and to vaccination kits for the immunization of poultry against *Ornithobacterium rhinotracheale*.

Over the last decades, in many countries a strong raise in both the number of poultry farms, and in addition, an increasing number of animals per farm has been seen. This situation has a serious consequence: large scale outbreaks of poultry diseases are seen more and more frequently. This in turn has caused an increasing need for new and better vaccines and vaccination programs in these countries.

Nowadays, most animals are immunized against a number of diseases of viral, bacterial and parasitic origin. Examples of bacterial agents infective to poultry are *Ornithobacterium rhinotracheale*, *Haemophilus paragallinarum* (Coryza), *Salmonella spp*, *Pasteurella multocida*, *Bordetella bronchiseptica* and *E. coli*. Examples of viral poultry pathogens are Newcastle Disease virus (NDV), Infectious Bronchitis virus (IBV), Turkey Rhinotracheitis virus (TRT), Herpesvirus of Turkeys (HVT), Fowlpox virus (FPV), Avian Reovirus (ARV), Infectious Laryngotracheitis virus (ILT), Marek's Disease Virus (MDV) and Infectious Bursal Disease virus (IBDV).

*Ornithobacterium rhinotracheale* is a relatively new bacterium causing a disease known for about a decade now, and found frequently in i.a. chickens and turkeys. Clinical signs in chickens are e.g. airsacculitis or coughing, pneumonic lungs or pleuritis. In turkey flocks in several parts of the world, a comparable infection of the respiratory tract is found. Mortality in flocks suffering from the disease can be as high as 5%. The first clinical signs are comparable to infection in chicken: sneezing and nasal discharge. In some animals clinical signs of acute infection are seen. Examination of sacrificed animals shows edema of the lungs, fibrinopurulent pneumonia and often serofibrinous pericarditis and serofibrinous infection of the airsacs. *Ornithobacterium rhinotracheale* is extensively described in European Patent EP0.625.190. Identification, serotyping and experimental infection in turkeys and chickens have been described e.g. by van Empel, P.C.M. et al., in Journ. of Clin. Microbiol. 35: 418-421 (1997), by van Empel, P.C.M. et al., in Avian Diseases 40: 858-864 (1996) and by van Empel, P.C.M. et al., in Avian Pathology 28:217-227 (1999). A review on *Ornithobacterium rhinotracheale* has been published in Avian Pathology 28: 217-227 (1999) by van Empel, P.C.M. and Hafez, H.M.

If an animal suffers from infection with a virulent pathogen, the immune system will try to remove the pathogen. Provided that the infected animal survives the infection, it usually develops a long-lasting immunity against the pathogen.

5 Vaccination with an attenuated pathogen mimics the natural infection in that it induces immunity, however without causing unacceptable clinical signs. Some clinical signs, in other words; some residual virulence, has to be accepted however because without this, the immune system will in most cases be insufficiently triggered. Generally spoken, vaccination is the way to avoid large scale infection and its negative consequences.

10 Vaccines against most of the known pathogenic bacteria and pathogenic viruses may comprise either inactivated or live attenuated pathogens, depending upon the purpose and the way of administration. But if it comes to efficient and early protection of young animals, combined with ease of application, live attenuated vaccines are clearly an attractive choice.

15 Such vaccines can be given from the day of birth, for poultry even *in ovo*, and if preferred, they can be applied from day of birth simply by spraying or through drinking-water application.

20 Spraying of vaccines is especially attractive for poultry and is currently applied on a very large scale for e.g.: Infectious Bronchitis virus, Newcastle Disease virus, Turkey Rhinotracheitis virus, Infectious Bursal Disease virus and Avian Reovirus.

The main disadvantage of vaccines derived from virulent pathogens is, that they must be carefully and sufficiently attenuated in order to be safe.

25 This requirement can relatively easily be fulfilled for highly virulent microorganisms, because they can in most cases be highly attenuated while remaining their vaccinating (immunity-inducing) capacities.

30 Of the bacteria mentioned above, *Ornithobacterium rhinotracheale* belongs to the so-called secondary pathogens. A secondary pathogenic bacterium is a bacterium that does not readily cause disease in healthy animals. As a consequence, the immune system will not or insufficiently be triggered and therefore, no immunity will develop.

In animals kept under sub-optimal conditions such as high stock density and stress, such secondary pathogenic bacteria can however cause dramatic morbidity and mortality.

35 Thus, for secondary pathogens, the design of a live attenuated vaccine is severely hampered by the unpredictable behavior of the bacteria. Unpredictable in the sense that the level of virulence of such bacteria does not solely depend on their level of attenuation, but (contrary to

what is the case for primary pathogens) also largely on the physical situation of the animal to be vaccinated.

This is a real dilemma as will be sketched below using *Ornithobacterium rhinotracheale* as example.

5

*Ornithobacterium rhinotracheale* is a relatively mild bacterium, in the sense that in perfectly healthy Specified Pathogen Free (SPF) poultry kept under optimal conditions it might be difficult to induce disease at all, even when using non-attenuated, wild-type, bacteria.

Thus, such poultry, be it chickens, turkeys or ducks, even when "vaccinated" with the wild-

10 type bacterium, are not affected and as a consequence they do not build up any protection against *Ornithobacterium rhinotracheale*. An example of a wild-type strain is the *Ornithobacterium rhinotracheale* strain 3263/91 as deposited at the Centraalbureau voor Schimmelcultures (CBS), Oosterstraat 1, P.O.box 273, 3740 AG Baarn, The Netherlands, under accession-number 400.92.

15

However, poultry kept under standard conditions for commercial breeding, i.e. a high stock density, stress, poor ventilation and/or high ammonia levels, are much more vulnerable to *Ornithobacterium rhinotracheale*. They are severely affected by wild-type *Ornithobacterium rhinotracheale* strains.

20 Especially if such animals would already suffer from another infection the effect could be dramatic. In animals suffering from (sometimes even sub-clinical) infections with other bacteria or viruses, the wild-type bacterium often causes massive and severe morbidity.

In addition to this and unlike other secondary pathogenic bacteria, the pathological effects of 25 any *Ornithobacterium rhinotracheale* strain in poultry not only depend on the virulence of the strain as such and the physical condition of the infected animal but, especially in the case of chickens, also heavily upon the chicken species. It is e.g. well-known in the art, that broilers are much more susceptible to *Ornithobacterium rhinotracheale* infection than layers.

30 For the reasons given above, the development of a live attenuated vaccine starting from a secondary pathogen in general and especially *Ornithobacterium rhinotracheale*, although possible, is complex to say the least. On the one hand, even a wild-type strain of these bacteria is not capable of inducing protection in perfectly healthy, less susceptible animals, whereas on the other hand even an attenuated strain is only suitable in some cases for use in 35 susceptible animals or animals suffering from stress and other negative environmental factors, the suitability highly depending upon the level of stress and the poultry species.

Only a live over-attenuated *Ornithobacterium rhinotracheale* strain would be safe under all circumstances in poultry industry and in both broiler chickens and layer chickens. An attenuated strain, let alone an over-attenuated strain, will however not trigger any immune reaction in healthy, less susceptible animals, because in such animals even the virulent strain

5 does not trigger an immune reaction.

---

This dilemma makes it difficult to provide vaccines based upon live secondary pathogens, more specifically *Ornithobacterium rhinotracheale*, that are both efficacious and safe, regardless the kind of animal to be vaccinated and its physical condition.

10 It is an objective of the present invention to provide vaccines that add to solving this dilemma.

In order to reach this goal, the present invention provides a combination vaccine for the protection of poultry against *Ornithobacterium rhinotracheale* wherein the combination

15 vaccine comprises a live over-attenuated *Ornithobacterium rhinotracheale* strain and a live attenuated poultry virus.

20 The present invention relates to the surprising finding that even over-attenuated secondary pathogenic *Ornithobacterium rhinotracheale* bacteria are well capable of inducing a protective response provided that they are given in combination with a live attenuated poultry virus. Such over-attenuated secondary pathogenic bacteria are inherently safe because they only cause moderate clinical signs even when they would accidentally be administered at a moment in time at which a field infection with a wild-type virus has occurred.

25 An over-attenuated *Ornithobacterium rhinotracheale* bacterium is a bacterium that (contrary to an attenuated *Ornithobacterium rhinotracheale* strain) is not capable of inducing a protective immune response to *Ornithobacterium rhinotracheale* in primed animals. A primed animal is an animal that has received, prior to administration of the vaccine, a virulent pathogen that predisposes for ~~infection with~~ secondary pathogenic bacterium.

30 Primed animals provide an objective animal model for testing the level of attenuation. Animals randomly taken from commercial farms would not provide a stable model, because inherently, their physical condition is difficult to establish and highly variable. Primed animals, contrary to this, are of known SPF-origin, they are by definition in good health and they received, as a priming, a well-defined amount of a well-defined pathogen.

35 The priming virus of choice for the chicken model is Newcastle Disease virus. Turkey Rhinotracheitis virus is the priming virus of choice in turkeys. Thus, in order to see if an attenuated *Ornithobacterium rhinotracheale* bacterium for use in chickens indeed behaves

over-attenuated in chickens, this should be tested in chickens primed with Newcastle disease virus, as is e.g. indicated in the Examples section.

A protective immune response is an immune response that gives, after challenge, a

5 statistically significant decrease in respiratory tract lesion score of equal or more than 50% compared to non-vaccinated animals. The respiratory tract lesion score test is explained in the Examples section.

The nature of the mutation(s) leading to the over-attenuated behavior is not critical. Many attenuating mutations known in the art are suitable. Suitable *Ornithobacterium rhinotracheale* 10 mutations are e.g. the classical PurD-, RecA- and Aro-mutations, known in the art for many bacterial species. Also, many temperature-sensitive mutants are suitable. Of these, PurD- and RecA-mutations are preferred. The PurD gene encodes a protein that is involved in the Purine ribonucleotide biosynthesis. A PurD-mutation is defined as a mutation that disturbs the Purine ribonucleotide biosynthesis in the sense that such a mutant makes less or less active or no 15 PurD gene product compared to wild type *Ornithobacterium rhinotracheale* strains. The RecA gene encodes a protein that is involved in recombination processes. A RecA-mutation is defined as a mutation that disturbs recombination processes in the sense that such a mutant makes less or less active or no RecA gene product compared to wild type *Ornithobacterium rhinotracheale* strains.

20 Mutations such as PurD- and RecA-mutations are most easily obtained by simply deleting the gene encoding PurD and RecA. Such (site-directed) mutation techniques are well-known in the art.

The level of attenuation of the live attenuated viral component of the combination vaccine 25 according to the invention is not critical. Usually, a live attenuated viral vaccine strain will be chosen that is suitable as a vaccine, i.e. a strain that induces protection against infection without causing an unacceptable level of pathogenicity. Many live attenuated viral poultry vaccines are commercially available. Such strains can simply be purchased from various producers.

30 Suitable live attenuated poultry viruses are e.g. Infectious Bronchitis virus, Turkey Rhinotracheitis virus, Newcastle Disease virus, Avian Reovirus and Marek's virus.

Examples of suitable live attenuated viral vaccine strains especially suitable in chickens are 35 e.g. Nobilis IB 4/91, D1466, D274, H120, H52 and MA5 (IBV), Nobilis ILT (ILT), Nobilis Marek THV, Rismavac, SB1 and Marexine CA126 (MDV) and Nobilis ND Broiler, Clone 30, Hitchner, LaSota, Nobilis NDC2/Nobilis Newhatch C2 and Nobilis MA5. Such vaccines are

available from Intervet International B.V., Wim de Korverstraat 35, 5831 AN Boxmeer, The Netherlands.

Nobilis Duck Plague is especially suitable for use in combination vaccines for ducks.

Nobilis TRT is especially suitable for use in combination vaccines for turkeys.

5

Preferably, the viral component of the combination vaccine is administered via the same route as the live over-attenuated *Ornithobacterium rhinotracheale* vaccine. *Ornithobacterium rhinotracheale* causes respiratory disease and sometimes severe inflammation reactions in the joints. These inflammation reactions are often seen when *Ornithobacterium rhinotracheale*

10 enters the blood stream. Therefore, a suitable route of administration especially for combating inflammation reactions in the joints is subcutaneous or intramuscular injection of both the bacterial component and a live attenuated poultry virus causing systemic reactions. Examples of viruses, preferred for administration in the combination vaccine according to the invention are live attenuated Avian Reovirus, preferably Nobilis Reo 1133 and 2177, and Marek's virus.

15

*Ornithobacterium rhinotracheale* being a mainly respiratory disease, a preferred route however would be oral/nostril/respiratory tract vaccination. A more preferred route of vaccination would be vaccination by spray/aerosol, since in that case, the combined components would most directly reach the respiratory tract and other spots where immunity is

20

most needed.

The preferred live attenuated viral components for oral- nostril- or respiratory tract application are those viruses known to cause respiratory disease, specifically Infectious Bronchitis virus, Turkey Rhinotracheitis virus and Newcastle Disease virus.

25

Of these, Nobilis TRT, Nobilis NDC2/Nobilis Newhatch C2 and Nobilis MA5 are the most preferred.

Although preferred, both the active components of the combination vaccine do not necessarily have to be administered in a mixed form. The way of administration for each component may

30

depend on the specific properties of each of the components. For example, although administration by injection of such vaccines is also contemplated, the live over-attenuated *Ornithobacterium rhinotracheale* vaccine strains are preferably administered by the inexpensive mass application techniques commonly used for vaccination and well-known in the art, such as spraying/aerosol or drinking water application. It is very well possible that the

35

viral component is preferably given through another route, e.g through parenteral administration.

Also other routes of administration are contemplated such as *in ovo* vaccination, of course with the proviso that the specific active component is able to evoke a protective immune response after administration.

5 Also, if both the bacterial and the viral component of a certain combination vaccine according to the invention would preferably be administered by spraying, this would not necessarily mean that they are both sprayed through the same nozzle. It could well be possible that, due to differences in viscosity of both the bacterial and viral component, the carriers and/or any excipients, both vaccine components are preferably sprayed through different nozzles.

10 Nevertheless, this would of course still lead to the beneficial and synergistic effect that both the viral and the bacterial component of the combination vaccine have: after all, they would both reach the respiratory tract and exert their joined beneficial effect. Thus, it goes without saying that such separate administration of both components still gives the surprising effect and therefore is within the scope of the invention.

15 The present invention relies upon the fact that the live attenuated viral component triggers the animal in such a way that the over-attenuated *Ornithobacterium rhinotracheale* vaccine strain stays longer in the respiratory tract and more severely attacks the system. In pathogen-free hosts, the bacterium will disappear within one or two days. Most live attenuated poultry viruses (e.g. vaccine viruses) stay in the respiratory tract for up to a week at least.

20 Therefore, the advantages of the present invention can also be achieved if the components of the combined vaccine are administered to the birds separated by a small interval of time. The unexpected synergistic effect as described in the present invention will e.g. readily be obtained if the live attenuated viral component is given in the period between seven days before, and

25 two days after the live over-attenuated *Ornithobacterium rhinotracheale* vaccine strain is given.

Therefore, combination vaccines of live over-attenuated *Ornithobacterium rhinotracheale* and a live attenuated poultry virus as described in the present invention include those combinations in which the live attenuated viral component is given in the period between seven days before, and two days after the live over-attenuated *Ornithobacterium*

30 *rhinotracheale* vaccine strain is given, and include those combinations in which the live attenuated viral component and the live over-attenuated *Ornithobacterium rhinotracheale* component are administered at different sites.

35 Merely as an additional example: the advantageous effect of the combination vaccine can also be obtained if one of the components, e.g. the live attenuated poultry virus is administered *in ovo* shortly before hatching, i.e. in the last quarter, preferably at day 18, and the live over-attenuated *Ornithobacterium rhinotracheale* vaccine strain is administered 0-7 days after

hatching by e.g. spraying. Preferably, the amount of time between both vaccinations preferably does not exceed 7 days.

Preferably, the vaccination with the combi-vaccine is at one day of age. In a more preferred 5 form of this embodiment, the live attenuated poultry virus and the live over-attenuated *Ornithobacterium rhinotracheale* vaccine strain are administered at the same time, if only for ease of application. In an even more preferred form, the live attenuated poultry virus and the live over-attenuated *Ornithobacterium rhinotracheale* vaccine strain are administered by means of spraying.

10 Spraying can be done through a coarse spray giving visible droplets, or through the use of a nozzle that provides a fine mist. The latter has the advantage that the vaccine more efficiently reaches the lower parts of the respiratory tract.

15 The vaccine according to the invention comprises an effective dosage of the active components, i.e. an amount of immunizing active component that will induce protective immunity in the vaccinated birds against challenge with *Ornithobacterium rhinotracheale* and preferably to the live attenuated viral component of the combination vaccine. (Induction of a protective immunity in the vaccinated birds against the viral component of the combination vaccine is of course desirable, but not in principle necessary).

20 As mentioned above, a protective immune response is an immune response that gives, after challenge, a (statistically significant) decrease in respiratory tract lesion score of equal or more than 50% compared to non-vaccinated animals. In poultry, a higher level of protection against *Ornithobacterium rhinotracheale* would e.g. follow directly from a comparison of 25 lesion scores of vaccinated versus non-vaccinated animals after challenge.

The *Ornithobacterium rhinotracheale* component can in principle be administered in a suitable dose of between  $10^3$  and  $10^{10}$  colony forming units.

Typically, the *Ornithobacterium rhinotracheale* component will be administered in a dose of 30 between  $10^5$  and  $10^8$  colony forming units.

The live attenuated poultry virus component will usually be given also in a dose of between  $10^3$  TCID<sub>50</sub> and  $10^7$  TCID<sub>50</sub>, although this might of course strongly depend upon the amount of viruses prescribed by the manufacturer of the live attenuated viral component.

The combination vaccine can be used as a primary vaccination, if desired followed by one or more booster vaccinations. The combined vaccine is also suited for incorporation in vaccination programs that also involve the use of other vaccines in a live or inactivated form. Merely as an example, broilers may be vaccinated at one day of age followed by a booster 5 immunization at 10-21 days. Laying stock or reproduction stock may be vaccinated at 1-10 days followed by booster vaccinations at 26-38 days and 16-20 weeks.

In a more preferred form, the combination vaccine comprises a combination of an over-attenuated *Ornithobacterium rhinotracheale* and Newcastle Disease virus, even more 10 preferably NCD Clone 30, obtainable from Intervet International B.V., Wim de Korverstraat 35, 5831 AN Boxmeer, The Netherlands.

In an still even more preferred form, the combination vaccine comprises a combination of an over-attenuated *Ornithobacterium rhinotracheale* and Newcastle Disease virus NDC2, as deposited at the CNCM of the Institut Pasteur, 25 Rue du Docteur Roux, Paris, France under 15 Accession number I-1614.

In another more preferred form, the combination vaccine comprises a combination of an over-attenuated *Ornithobacterium rhinotracheale* and a live attenuated Turkey Rhinotracheitis virus, even more preferably Nobilis TRT, obtainable from Intervet International B.V., Wim 20 de Korverstraat 35, 5831 AN Boxmeer, The Netherlands.

In again another more preferred form, the combination vaccine comprises a combination of an over-attenuated *Ornithobacterium rhinotracheale* and a live attenuated Infectious Bronchitis virus, even more preferably Nobilis MA5, obtainable from Intervet International B.V., Wim 25 de Korverstraat 35, 5831 AN Boxmeer, The Netherlands.

In still another more preferred form, the combination vaccine comprises a combination of an over-attenuated *Ornithobacterium rhinotracheale* and a live attenuated Avian Reovirus, even more preferably Nobilis Reo 1133 or 2177, obtainable from Intervet International B.V., Wim 30 de Korverstraat 35, 5831 AN Boxmeer, The Netherlands.

The invention also relates to combination vaccines comprising, in addition to the two active components defined above, one or more additional antigens derived from a virus or micro-organism pathogenic to poultry or genetic information encoding said antigen.

35 More preferably, the virus or micro-organism is selected from the group consisting of Infectious Bronchitis virus, Infectious Bursal Disease (Gumboro), Chicken Anaemia agent,

Avian Reovirus, *Mycoplasma gallisepticum*, Turkey Rhinotracheitis virus, *Haemophilus paragallinarum* (Coryza), Chicken Poxvirus, Avian Encephalomyelitisvirus, Duck Plague virus, Egg Drop syndrome virus, Infectious Laryngotracheitis virus, Herpes Virus of Turkeys, Eimeria species, *Ornithobacterium rhinotracheale*, *Pasteurella multocida*, *Mycoplasma synoviae*, *Salmonella* species and *E. coli*.

The vaccine according to the invention can be prepared and marketed in the form of a suspension, or in a lyophilized form and additionally contains a pharmaceutically acceptable carrier customarily used for such active components. Carriers include stabilisers, diluents, preservatives and buffers.

10 preservatives and buffers.

Suitable stabilisers are for example SPGA, carbohydrates (such as dried milk, serum albumin or casein) or degradation products thereof. Suitable buffers are for example alkali metal phosphates. Suitable preservatives are thimerosal, merthiolate and gentamicin. Diluents 15 include water, aqueous buffers (such as buffered saline), alcohols and polyols (such as glycerol).

If desired, the vaccine according to the invention may contain an adjuvant. Suitable 20 compounds or compositions for this purpose include alum hydroxide, -phosphate, or -oxide, oil-in-water or water-in-oil emulsions based upon for example mineral oil, such as Bayol F® or Marcol 52® or a vegetable oil such as vitamin E acetate, and saponins.

Preferably, both the bacterial and the viral component of the combination vaccine according 25 to the invention are packaged in a mixed form in the same container. They could be freeze-dried or stored at low temperature thereafter.

The present invention also contemplates a kit format which comprises a packaged multi-container unit having containers each comprising one of the active components as defined above. The kit may additionally ~~comprise a carrier~~ with a carrier for one or both of the 30 active components, in which case the carrier preferably comprises an adjuvant. Such a kit is e.g. advantageous in case the active components are preferably not freeze-dried or premixed together, or when the active components are preferably administrated separated in place and/or time.

The active components of the kit according to the invention, i.e. the live over-attenuated 35 *Ornithobacterium rhinotracheale* strain and the live attenuated poultry virus, and possibly a third and further active components, can be mixed prior to vaccination, or administered

separately, at different administration sites and/or different moments of administration with the proviso's indicated above.

Still another embodiment of the present invention relates to the use of a live over-attenuated  
5 *Ornithobacterium rhinotracheale* strain and a live attenuated poultry virus for the  
manufacturing of a combination vaccine for the protection of poultry against  
*Ornithobacterium rhinotracheale*.

Also, another embodiment relates to the use of a live over-attenuated *Ornithobacterium*  
10 *rhinotracheale* strain and a live attenuated poultry virus for the manufacturing of a  
combination vaccine for the protection of poultry against *Ornithobacterium rhinotracheale*,  
wherein the live over-attenuated *Ornithobacterium rhinotracheale* strain and the live  
attenuated poultry virus are administered simultaneously, separately or sequentially.  
Simultaneous administration is administration of the live over-attenuated *Ornithobacterium*  
15 *rhinotracheale* strain and the live attenuated poultry virus at the same moment in time,  
preferably injected as a mixture, sprayed as a mixture sprayed from one nozzle or given as a  
mixture in the drinking water. Separate administration is administration of the live over-  
attenuated *Ornithobacterium rhinotracheale* strain and the live attenuated poultry virus from  
two different injection sites or, when sprayed, e.g. from two different nozzles, preferably at  
20 the same moment in time. Sequential administration is administration during which the live  
over-attenuated *Ornithobacterium rhinotracheale* strain and the live attenuated poultry virus  
are administered at different moments in time. The conditions for the various moments of  
administration are discussed above.

25 Again another embodiment of the present invention relates to methods for the preparation of a  
combination vaccine for the protection of poultry against *Ornithobacterium rhinotracheale*.  
Such methods comprise the admixing of a live over-attenuated *Ornithobacterium*  
*rhinotracheale* strain, a live attenuated poultry virus and a pharmaceutically acceptable  
carrier.  
30 Such methods may also and/or alternatively comprise the packaging of a live over-attenuated  
*Ornithobacterium rhinotracheale* and a live attenuated poultry virus in separate containers  
that form part of a kit.

**EXAMPLES****Example 1****Preparation of live over-attenuated *Ornithobacterium rhinotracheale* strains.**

5 Two commonly known attenuation targets, viz. *purD* and *recA*, were selected to create mutants.

Since serotype A strains are the most predominant and is also known to provide cross-protection against infections with other serotypes, this serotype was used to create the mutants.

10

**Bacterial strains and plasmids**

*Escherichia coli* host strains TOP10 and TOP10F' were purchased from Invitrogen (Carlsbad, CA). pUC19 was derived from Clontech laboratories (Palo Alto, CA).

15 An *Ornithobacterium rhinotracheale* strain serotype A (OR-7 (O95264 95.2932) Van Empel, P.C.M.; Molecular identification of *Ornithobacterium rhinotracheale*; (1998) ISBN 90-393-1574-4. Page 45.) was used as host strain for electroporation and homologous recombination. Chromosomal DNA of *Ornithobacterium rhinotracheale* strain 3263/91 (see above) was used as PCR template for making deletion constructs.

20 **Culture media, buffers and antibiotics**

Luria-Bertani (LB) broth and terrific broth (TB, Sambrook, J., E.F. Fritsch, and T. Maniatis. Molecular cloning: a laboratory manual. (1989) Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.) were used for liquid growth of bacterial *Escherichia coli* strains. For *Ornithobacterium rhinotracheale* (OR) Todd Hewitt (Becton Dickinson, Franklin Lakes, NJ, 25 non irradiated) was used. For OR on plates, blood agar or Todd Hewitt agar supplemented with 4% sheep blood was used. LB agar plates were poured from melted LB-agar, which was cooled to 45°C and then the appropriate antibiotics were added.

**Oligonucleotides**

30 All oligonucleotides were obtained from Life Technologies™ Gibco BRL (Paisley, UK) and are indicated in Table 1. Their location in the sequence is shown in figure 2A and B.

**PCR amplification**

PCR amplification was performed where the PCR mixture for cloning the *recA* and *purD* genes consisted of 40 U/ml of SuperTaq plus; 1x SuperTaq PCR buffer; 80 µM (each) of dATP, dCTP, dGTP and dTTP (HT BioTechnology Ltd., Cambridge, UK); 0.4 µM of both oligonucleotides and 1 µl of chromosomal DNA as template. Samples were analyzed on an

agarose gel. For the overlap extension PCR (OE-PCR) the first PCR products were diluted a hundred fold and mixed 1:1. Then PCR was performed with the outer primers as described below.

The colony PCR method was performed as follows: part of the colony was picked from an 5 agar plate and transferred into a PCR tube. The PCR mixture was added, containing: 10 U/ml of SuperTaq DNA polymerase; 1x SuperTaq PCR buffer; 80  $\mu$ M (each) of dATP, dCTP, dGTP and dTTP (HT BioTechnology Ltd., Cambridge, UK) and 0.4  $\mu$ M of both oligonucleotides. Samples were analyzed on an agarose gel.

10 Table 1. Oligonucleotides (primers) used for preparation of insertion-deletion constructs.

Primer Name	Sequence (5' → 3')	Features
<i>PurD</i> -F13	CTTA <u>AGCTT</u> GGATCCTTGTGGCGTGGCTT <sup>AG</sup>	<i>HindIII</i> site (underlined)
<i>PurD</i> -OE-R	<i>CTTCTAGCGT</i> AGCGCC <u>CAGATC</u> TCA <u>TTTGTTCGGT</u> TCCAGCGTTTCC	<i>BglII</i> site (underlined) and overlap with <i>PurD</i> -OE-F (italics)
<i>PurD</i> -OE-F	<i>GAGATC</i> GGCGCTACGCTAGAAGAAGCC	<i>BglII</i> site (underlined) and overlap with <i>PurD</i> -OE-R (italics)
<i>PurD</i> -R8	CTTA <u>AGCTT</u> CAGTGGAGCGGCAGATA <u>CAGAG</u>	<i>HindIII</i> site (underlined)
<i>RecA</i> -F6	CTTA <u>AGCTT</u> GGAGCGTGTAGTGCTCGCCATCG	<i>HindIII</i> site (underlined)
<i>recA</i> -OE-R	<i>ACCGCACGCACGAGA</i> <u>GATCT</u> CGGGCTTGTGCGCC ATCATCATCAC	<i>BglII</i> site (underlined) and overlap with <i>recA</i> -OE-F (italics)
<i>recA</i> -OE-F	<i>CGAGATCTCGT</i> GC <u>GTGCGGT</u> TATTGAAAG	<i>BglII</i> site (underlined) and overlap with <i>recA</i> -OE-R (italics)
<i>RecA</i> -R5	CTTA <u>AGCTT</u> CCCAGCCAATCGGCTCGTTTAC	<i>HindIII</i> site (underlined)

#### Nucleotide sequence analysis

The nucleotide sequences of the *purD* and *recA* genes and their surroundings were determined.

15 Sequencing was performed using a cycle sequencing protocol on a Perkin Elmer 9700 DNA thermal cycler with big dye terminators: approx. 50 ng of PCR product, 2  $\mu$ l terminator ready reaction mix (Perkin Elmer, CA) 2.4 pmoles of primer, 6  $\mu$ l of buffer (200 mM Tris-HCl pH8.5; 5mM MgCl<sub>2</sub>) and aqua dest in a total of 20  $\mu$ l.

#### 20 DNA manipulations

For sequencing, the *purD* and *recA* genes and their flanking regions were amplified by PCR and cloned into a general purpose cloning vector.

**Electroporation of *Ornithobacterium rhinotracheale*.**

*Ornithobacterium rhinotracheale* was made electro-competent by growing in Todd-Hewitt broth until an OD 600 nm of 0.3. During further manipulations, the cells were kept on ice.

5 The culture was washed twice with ice-cold water and once with ice cold 10 % glycerol. This suspension was centrifuged again and the cells were resuspended in 0.5 ml of 10% glycerol and stored on ice until use.

Electroporation was performed using a BTX ECM630 GenePulser (San Diego, CA). 1–2  $\mu$ g of plasmid DNA was mixed with 50  $\mu$ l of electro competent *Ornithobacterium rhinotracheale* cells in a 2 mm cuvette. A pulse of 20-24 msec. was delivered using 2500V; HV capacity; 25  $\mu$ F and 800  $\Omega$ . After electroporation, 1 ml of TH broth was added and the cells were recovered for 2 hours at 37°C and 100 RPM. Viability was checked on blood agar plates. Antibiotic resistant colonies were selected on TH agar with 4 % blood and antibiotic at a selective concentration.

15

**UV-sensitivity of *recA* recombinants.**

In order to check a recombination in the *recA* gene, its sensitivity to UV was tested. Bacteria were plated onto blood agar and UV irradiated with a wavelength of 365 nm at a distance of about 10 cm. Different exposure times were tested, ranging from 0 to 120 seconds. Plates 20 were then incubated and growth of *recA*-mutant colonies were compared to growth of *purD*-mutant colonies and colonies of the wild type strain.

## RESULTS

**Sequencing *recA* and *purD*.**

25 To obtain the sequence of the *purD* and *recA* genes of *OR*, degenerate primers were developed based on conserved regions of the genes derived from closely related bacteria. By means of genome walking, the flanking regions were determined. The complete sequences and the relevant features are shown in figure 2A for *purD* and figure 2B for *recA*.

30 **Construction of the *recA* and *purD* deletion and insertion-deletion constructs.**

The strategy for construction an insertion-deletion mutant is depicted in Figure 1.

For the *purD* mutant the procedure was as follows. First, PCR on genomic *Ornithobacterium rhinotracheale* DNA was performed using 2 primer sets *purD*-F13 (+*HindIII* site) with *purD*-OE-R (upstream *purD*) and *purD*-OE-F with *purD*-R8 (+*HindIII* site) (downstream *purD*) to 35 amplify the flanking regions of the *purD* gene. Overlap-extension PCR was performed with the *purD*-F13 and the *purD*-R8 primers using both *purD* PCR fragments as templates since the OE-R and OE-F primers overlap. This results in PCR fragments that contain both flanking

regions of the *purD* gene and therefore the biggest part of the *purD* gene is deleted. These fragments were digested with *HindIII* and cloned into pUC19. Then an antibiotic resistance marker present on a 1.2 kb *BamHI* fragment was introduced in the *BglII* site that was included in the overlap sequence of the OE-F and OE-R primers.

5 A similar approach was followed for construction of the *recA* insertion-deletion construct. Primers *recA*-F6 and *recA*-OE-R (upstream *recA*), and *recA*-OE-F and *recA*-R5 (downstream *recA*) were used in PCR for the flanking regions of the *recA* gene. OE-R and OE-F primers overlap and have an additional *BglII* site for insertion of the antibiotic resistance marker. The constructs were verified, plasmid DNA was isolated and used to electroporate

10 *Ornithobacterium rhinotracheale*.

**Verification of the mutation in recombinants.**

After electroporation, colonies were obtained for both the *recA* and *purD* constructs, that showed antibiotic-resistance.

15 Mutants for both genes were confirmed by PCR. The *recA* mutant clones were additionally confirmed by testing for their sensitivity to UV irradiation; the *purD* mutants and the parent strain were able to survive UV exposure times for more than 40 sec whereas the *recA* mutant died after 10 sec of irradiation.

20

**Example 2**

**Comparison of induction of protection of over-attenuated *Ornithobacterium rhinotracheale* strains.**

Vacc. 2 weeks $2 \times 10^7$ CFU/ml	Prim. Day 23	Chall. Day 28 $3 \times 10^8$ CFU	Resp. score.
<i>O.r. RecA</i>	NDV	100 ml spray	46
<i>O.r. PurD</i>	NDV	100 ml spray	35
—	NDV	100 ml spray	51

25

**Table 2: comparison of level of protection of over-attenuated mutants.** Vaccine strains were applied by spraying. Each group consisted of 15 chickens. Challenge was done with wild-type. Respiratory scores are given as a percentage of the maximally possible score of the challenged group.

30

The affected organs of the birds were scored in a numerical scoring system:

Thoracic air sacs (TAS): 0 = no abnormalities, 1 = one air sac seriously affected by fibrinous airsacculitis or limited pinhead-sized foci of fibrinous exudate in both air sacs, 2 = both air sacs seriously affected by fibrinous airsacculitis.

Abdominal air sacs (AAS): 0 = no abnormalities, 1 = pinhead-sized foci of fibrinous exudate

5 or slight diffuse airsacculitis, 2 = severe fibrinous airsacculitis.

Pneumonia: 0 = no abnormalities, 1 = unilateral pneumonia, 2 = bilateral pneumonia.

Trachea: 0 = no abnormalities, 1 = some exudate in the tracheal lumen, 2 = lumen of trachea filled with exudate.

10 Table 2 shows the result of a vaccination experiment in which two weeks old chickens were vaccinated by spray-vaccination of  $2*10^7$  CFU in 100 ml spray solution of a RecA-mutant and a PurD-mutant of *Ornithobacterium rhinotracheale*. Priming was done with an NDV Lasota vaccine strain at day 23, and challenge with a wild-type *Ornithobacterium rhinotracheale* strain was done at day 28. The level of protection was determined by counting the trachea and 15 lung lesions.

The figures of the respiratory lesion score (see column resp. score in table 2) are to be interpreted as follows: the maximal possible lesion score is taken as 100% score. Non-vaccinated animals show a lesion score of 51%, and "vaccinated" animals have a lesion score 20 of 46% (RecA) or 35% (PurD). This means that "vaccination" with RecA or PurD gives a level of protection of 8% ( $100\% - (46*100\%/51)$ ) or 30% respectively.

A protective immune response, as defined above, is an immune response that gives, after challenge, a (statistically significant) decrease in respiratory tract lesion score of equal or more than 50% compared to non-vaccinated animals.

25 It follows from table 2 that the respiratory lesion score of the groups that received vaccination with a mutant of *Ornithobacterium rhinotracheale* does not significantly differ from the respiratory lesion score found with the non-vaccinated animals.

Conclusion: a RecA-mutant and a PurD-mutant of *Ornithobacterium rhinotracheale*, if given as such, are not capable to raise a protective immune response in chickens.

Example 3

Comparison of induction of protection of over-attenuated *Ornithobacterium rhinotracheale* strains after priming and boosting.

Vacc. Day 1 $2 \times 10^7$ CFU/ml-strain	Boost 2 weeks $2 \times 10^7$ CFU/ml-strain RecA	Prim. Day 23	Chall. Day 28 A: $4 \times 10^7$ Spray	Resp. score
RecA				
--	--	NDV	A	27
Nostr./conj.0.2 ml	Spray 100 ml	NDV	A	19 <sup>b</sup>

5

Table 3: comparison of level of protection obtained with over-attenuated mutants after a first administration followed by a booster administration. Each group consisted of 12 chickens.

Respiratory scores are given as a percentage of the maximally possible score of the challenged group. Challenge was done with wild-type

10 (b) not statistically different from non-vaccinated control.

Table 3 shows the result of a vaccination experiment in which chickens have been vaccinated first in the nostrils and then boosted after two weeks by spray-vaccination using a RecA-mutant of *Ornithobacterium rhinotracheale*. Priming was done with an NDV Lasota vaccine strain at day 23, and challenge with a wild-type *Ornithobacterium rhinotracheale* strain was done at day 28. The level of protection was determined by counting the respiratory lesions. As can be seen in the last column, the respiratory lesion score of the groups that received two subsequent vaccinations with a RecA-mutant of *Ornithobacterium rhinotracheale* does not significantly differ from the respiratory lesion score found with the non-vaccinated animals.

15 Conclusion: a RecA-mutant of *Ornithobacterium rhinotracheale* is not capable, even when given twice, to raise a protective immune response in chickens.

20

**Example 4****Induction of lesions by over-attenuated mutants and wild-type strains.**

Prim. Day	Chall. Day 28	Resp. score.
23	100 ml spray	
NDV	RecA $7 \times 10^7$	22
NDV	PurD $2 \times 10^8$	24
NDV	Wild-type	59

5 **Table 4:** comparison of induction of lesions by over-attenuated mutants and wild-type strains. Each group consisted of 12 chickens. Respiratory scores are given as a percentage of the maximally possible score of the challenged group.

10 Table 4 shows the results of challenge with both an RecA-mutant, a PurD-mutant and a wild-type strain of *Ornithobacterium rhinotracheale*. No vaccination took place prior to priming and challenge. As can be seen from the last column, the mutants give a respiratory lesion score that is less than half the respiratory lesion score found after challenge with the wild-type strain. This clearly shows that the mutants behave mild, even without prior vaccination, and even after priming with a relatively "hot" NDV-strain, i.e. the Lasota strain.

15

**Example 5****Comparison of protection of *Ornithobacterium rhinotracheale*/NDV combination vaccines after subsequent challenge.****Experimental design**

20 A 125 1-day-old SPF broiler chickens were used. At 1-day-old all chickens were spray vaccinated with live attenuated NDV and subsequently groups of 25 chickens were aerosol vaccinated with either of the mutant strains *recA* and *purD* or the wild type strain 3263/91 (serotype A) or were left unvaccinated (challenge controls). At 9 days after vaccination 10 chickens of each group were sacrificed for post-mortem examination to assess the safety of each vaccine. The remaining chickens (15 per group) were spray treated with ND-Lasota at 25-days of age and aerosol challenged with wild-type *Ornithobacterium rhinotracheale* 3263/91 (serotype A) at 31 days of age. Seven birds of each group were additionally challenged intravenously. At 38 days of age the chickens were killed and post-mortem examined to assess the efficacy of each vaccine.

In addition to a non-*Ornithobacterium rhinotracheale*-vaccinated challenge control group, a non-*Ornithobacterium rhinotracheale*-vaccinated and non-challenged control group was used as NDV-control group.

The detailed experimental design and treatment schedule is shown in Table 5.

5

*Ornithobacterium rhinotracheale* vaccine cultures

For aerosol vaccination with the wild type *Ornithobacterium rhinotracheale* 3263/91 (serotype A), *recA* and *purD*, fresh cultures in Todd-Hewitt broth containing  $6.7 \times 10^8$  CFU/ml,  $3.9 \times 10^7$  CFU/ml and  $2.6 \times 10^8$  CFU/ml, respectively, were used. The dose for aerosol vaccination was 100 ml per isolator.

10

ND suspensions

NDV-strain NDC2 has been deposited at, and is obtainable as Nobilis NDC2/Nobilis Newhatch C2, or from the CNCM of the Institut Pasteur, 25 Rue du Docteur Roux, Paris, France under Accession number I-1614. ND-Lasota was obtained from Intervet Int. B.V. (see above). The dose for NDC2 was  $10^{6.4}$  EID<sub>50</sub> per animal (corresponding to 2ml per bird) and for ND-Lasota  $10^{6.6}$  EID<sub>50</sub> per animal (corresponding to 3 ml per bird), using a 1 L spray can.

15

*Ornithobacterium rhinotracheale* challenge culture

For aerosol challenge a fresh culture of wild-type *Ornithobacterium rhinotracheale* strain 3263/91 (serotype A) in Todd-Hewitt broth containing  $4.3 \times 10^8$  CFU per ml (as determined by plate counting) was used.

20

Animals: 125 1-day-old SPF Hybro broilers were used.

25

Grouping and dosing (vaccination / challenge)

Chickens were randomly divided (as they came to hand) over the different isolators and were treated as shown in Table 5.

NDC2 (1-day-old) or ND-Lasota (25-day-old) were given by spray using a 1 L spray can: 2ml per bird or 3 ml per bird, respectively. The birds remained in the spray for 10 minutes with the air-circulation closed. At 1-day-old the birds were first treated with NDC2 and subsequently with *Ornithobacterium rhinotracheale*.

*Ornithobacterium rhinotracheale* vaccine (1-day-old) as well as *Ornithobacterium rhinotracheale* challenge (31-day-old) was given by aerosol at a dose of 100 ml per isolator using a paint sprayer.

After the aerosol challenge 7 birds of each group were additionally challenged intravenously at a dose of 1 ml into the wing vein.

Post mortem investigations

Birds that died during the experiment were subjected to a post-mortem examination to determine the cause of death.

5 At 10-day-old (9 days after vaccination) 10 birds per group were sacrificed and subjected to a post-mortem examination to assess the safety (attenuation) of the (vaccine) strains compared to the wild type. At 38 days of age (7 days after challenge) the (remaining) challenged birds were killed and also subjected to a post-mortem examination to assess the efficacy of the different strains.

10 The affection rates of the groups are given as a percentage of the maximal possible lesion score of the group.

Statistical analysis

The total lesion scores per group (compared to the controls) were analysed two-sided using

15 the non-parametric Mann-Whitney U test. The level of significance was set at 0.05.

Results and conclusion

Concurrent aerosol vaccination at 1-day-old with live attenuated NDV and wild type

*Ornithobacterium rhinotracheale* induced unacceptable lesions after vaccination but also (as a result of that) induced a strong protective response as evidenced after challenge where this group had the least post-mortem scores. Apparently, the initial lesions caused by the vaccination had already disappeared at time of challenge.

Concurrent aerosol vaccination at 1-day-old with live attenuated NDV and *recA* or *purD* mutant *Ornithobacterium rhinotracheale* strains demonstrated a good level of safety as well as efficacy.

As follows from table 5, concurrent aerosol vaccination of 1-day-old SPF broilers with live attenuated NDV and *recA* or *purD* mutant strains appeared safe and to induce a good level of immunity against challenge with wild type *Ornithobacterium rhinotracheale*.

30

Example 6

Comparison of protection of *Ornithobacterium rhinotracheale/MA5* combination vaccines after subsequent challenge.

In this experiment, Infectious Bronchitisvirus type MA5 was used as the live attenuated viral component. Additionally, the experiment with *Ornithobacterium rhinotracheale*/NDV combination vaccines was repeated.

5 The experimental set-up of this Example was largely identical to that of Example 5. Where different numbers of animals or different moments of vaccination or challenge apply, this is indicated in table 6. This table also gives an overview of the vaccines used and the vaccination schedule, as well as the level of protection obtained.

10 MA5 suspensions: live attenuated Infectious Bronchitisvirus (IBV) type MA5 (Intervet International B.V., Wim de Korverstraat 35, 5831 AN Boxmeer, The Netherlands) was used at a concentration of  $5.5 \log^{10}$  EID<sub>50</sub> per animal, and applied by spraying.

#### Conclusion

15 As follows from table 6, concurrent aerosol vaccination of 1-day-old SPF broilers with IBV MA5 and PurD-mutant strains induces a good level of immunity against challenge with wild-type *Ornithobacterium rhinotracheale*. Additionally it follows from table 6, that concurrent aerosol vaccination of 1-day-old SPF broilers with NCD and PurD-mutant strains induces a good level of immunity against challenge with wild-type *Ornithobacterium rhinotracheale* as was also demonstrated in Example 5.

table 5

group	no. of chickens	Treatment			Results	
		vaccination at day 1	challenge at day 25	challenge at day 31	% of max ainsac score at day 10 (safety)	% of max ainsac score at day 38 (efficacy)
1	25	NDV	RecA aerosol	NDV	WT-OR aerosol	2.5
2	25	NDV	PurI aerosol	NDV	WT-OR aerosol	7.5
3	25	NDV	WT-OR aerosol	NDV	WT-OR aerosol	68
4	25	NDV		NDV	WT-OR aerosol	0
5	25	NDV		NDV	WT-OR aerosol	0

<sup>b</sup> Significantly different ( $p<0.05$ ) compared to the controls (group 1) using two-sided Mann-Whitney U test

table 6

group	n. of chickens	Treatment		Results	
		vaccination at day 1	day 30	challenge day 35	% reduction
1	15	NDV	PuD aerosol	NDV	WT-QR aerosol
2	15	NDV	PuD aerosol	NDV	WT-QR aerosol
3	15	NDV	NDV	NDV	WT-QR aerosol
4	15	MAS	MAS	NDV	WT-QR aerosol
5	15	MAS	PuD aerosol	NDV	WT-QR aerosol

<sup>b</sup> Significantly different ( $p<0.05$ ) compared to the controls (group 1) using two-sided Mann-Whitney U test

**Legend to the figures**

**Figure 1: cloning strategy for making mutation constructs of *recA* and *purD* genes in OR.**  
Overlap extension PCR was used to create a deletion in the open reading frame of the gene of interest and these fragment were cloned in pUC19. Subsequently an antibiotic resistance marker gene (BamHI fragment) was cloned into the BglII site of the gene of interest (insertion-deletion constructs).

---

**Figure 2A: Sequence of *purD* and localization of primers used for cloning and verification of mutants.**

**Figure 2B. Sequence of *recA* and localization of primers used for cloning and verification of mutants**

## Claims

- 1) A combination vaccine for the protection of poultry against *Ornithobacterium rhinotracheale*, characterized in that said combination vaccine comprises a live over-attenuated *Ornithobacterium rhinotracheale* strain and a live attenuated poultry virus.
- 2) A combination vaccine according to claim 1, characterized in that said live attenuated poultry virus is Infectious Bronchitis virus, Newcastle Disease virus, Turkey Rhinotracheitis virus, Marek's virus or Avian Reovirus.
- 3) A combination vaccine according to claim 1, characterized in that said live attenuated poultry virus is Infectious Bronchitis virus, Newcastle Disease virus or Turkey Rhinotracheitis virus.
- 4) A combination vaccine according to claim 1, characterized in that said live attenuated poultry virus is Newcastle Disease virus.
- 5) A combination vaccine according to claim 1, characterized in that said live attenuated poultry virus is Newcastle Disease virus type NDC2.
- 6) A combination vaccine according to claim 1, characterized in that said live attenuated poultry virus is Turkey Rhinotracheitis virus.
- 7) A combination vaccine according to claim 1, characterized in that said live attenuated poultry virus is Infectious Bronchitis virus.
- 8) A combination vaccine according to claims 1-7, characterized in that said live over-attenuated *Ornithobacterium rhinotracheale* has a mutation, said mutation preferably being a deletion, in the *purD*-gene or the *recA*-gene.
- 9) A combination vaccine according to claims 1-8, characterized in that said combination vaccine comprises an additional antigen derived from a virus or micro-organism pathogenic to poultry or genetic information encoding said antigen.
- 10) A combination vaccine according to claim 9, characterized in that the virus or micro-organism is selected from the group consisting of Infectious Bronchitis virus,

Infectious Bursal Disease (Gumboro), Chicken Anaemia agent, Avian Reovirus, *Mycoplasma gallisepticum*, Turkey Rhinotracheitis virus, *Haemophilus paragallinarum* (Coryza), Chicken Poxvirus, Avian Encephalomyelitisvirus, Duck Plague virus, Egg Drop syndrome virus, Infectious Laryngotracheitis virus, Herpes Virus of Turkeys, Eimeria species, *Ornithobacterium rhinotracheale*, *Pasteurella multocida*, *Mycoplasma synoviae*, *Salmonella* species and *E. coli*.

---

- 11) Use of a live over-attenuated *Ornithobacterium rhinotracheale* strain and a live attenuated poultry virus for the manufacturing of a combination vaccine for the protection of poultry against *Ornithobacterium rhinotracheale*.
- 12) Use of a live over-attenuated *Ornithobacterium rhinotracheale* strain and a live attenuated poultry virus for the manufacturing of a combination vaccine for the protection of poultry against *Ornithobacterium rhinotracheale*, wherein the live over-attenuated *Ornithobacterium rhinotracheale* strain and the live attenuated poultry virus are administered simultaneously, separately or sequentially.
- 13) Method for the preparation of a combination vaccine according to claims 1-10, characterized in that said method comprises the admixing of a live over-attenuated *Ornithobacterium rhinotracheale* strain, a live attenuated poultry virus and a pharmaceutically acceptable carrier.
- 14) A vaccination kit for the immunization of poultry against *Ornithobacterium rhinotracheale*, characterized in that said kit comprises
  - a) a live over-attenuated *Ornithobacterium rhinotracheale* strain and
  - b) a live attenuated poultry virus and
  - c) optionally a pharmaceutically acceptable carrier for the component under a and/or b.
- 15) A vaccination kit according to claim 14, characterized in that the carrier comprises an adjuvant.

**Abstract**

The present invention relates to a combination vaccine for the protection of poultry against *Ornithobacterium rhinotracheale*, to the use of a live over-attenuated *Ornithobacterium rhinotracheale* strain and a live attenuated poultry virus for the manufacturing of such a combination vaccine, to methods for the preparation of said combination vaccine and to vaccination kits for the immunization of poultry against *Ornithobacterium rhinotracheale*.

---



Figure 1. Overlap-extension-PCR fragment with purD deletion

Overlap-extension-PCR fragment with recA deletion




Figure 2A.

1 GTTCGACCAA ACGGCTTGTT GTGCGGTGAA ACATAGCACT CCTTGTGGCG TGGCTTTAGA TGATGATATT TTGCAAGCGT  
>>.....F5.....>> CTTAAGCTTGGAA>>.....F13.....>>

*HindIII*

81 ACCAAAAAGC ACACGACTGC GACCCGATTT CGATTTTG TGCCATTGTA ACTTTTAATA AAAAAAGTAAC AAAAGCAGTG  
161 GCAGAAAAAT GTAACCGAGAT TTTCCCTTGAA ATCGTTGCTG CACCGAGCTT TGAGCCAGAG GCTTTGGAAAG TTTTGCTAA  
241 AAAGAAAAAT TTGCGCGTGA TTGAAGTTAA AAATCCATTA AGCGATAAAA TGCAACTCGT GCAAGTAGAT GGCGGATTGC  
321 TCGTGCAAGA AATCGACAAA TCGTTTAGCA ATGATTTAA AGTAGTAACC GAAAACAAAC CTACCGAAAAA GCAACTTTCT  
401 GATTTGGAAT TTGCCATGAA AGTAGTGAAA CATGTAAAGA GCAATGCCAT CGTGGTTGCC ACAAACGGAC AAGCTCTAGG  
481 CGTGGGCACA GGCGAGACTA ATCGTATTG GGCAGCACAG CAGGCGATTC AGCGTGCAGA GGAAAAAAACA CAAGAAAATC  
561 TAGTTTGGC TTCCGATGCC TTTTCCCCT TCAGAGATGT GGTAGATTAT GCAGCACAAAG AAGGCATTAC AGCCTTGATT  
641 CACCCAGGAG GAAGCATGCG CGACCAAGAG AGCATAGACG CGGCTAATGA ACACGGAATC CCGATGATCA TCAGCGGTAT  
721 GAGACATTTC TTACATTAAA TCAAAAAATC TAAACAATAA TTATCAATAA TTCTAAAACA CAATAAGTAT GAATGCAAAT  
>>...*purD*...>

801 GATTACAAA AAATACTCAT CGTAGGAAAC GGCGCAAGAG AACACGCCAT CGGGTGGAAA ATTAAACAAG ACCACCCCTTC  
>.....*purD*.....>

881 TTGCGAGCTT TTCTTGGCGC CAGGAAACGC TGGAACCGAA CAAATTGGAA AAAACATCGT AGCTGAATCT AATTATGGCT  
>.....*purD*.....>  
<<.....OE-R.....<<AGATCTGGCGCTACGCTAGAAG

*BglII*

961 TAATGCTTT TGCTCAACAA AATGATATAG ACTTAACGAT TGTAGGTCCA GAAGCAGAAT TGGTAGAAGG TATTGTAGAC  
>.....*purD*.....>

1041 TTGTTTGAAT CCAATCAATT AAGAATTGGT GGTCCAGATA AGCGTGCAGC TAAATTGGAA GGCAAGCAAGG CTTTGCCAA  
>.....*purD*.....>

1121 AGATTTTATG GAGAAATACG GCGTGCAC GGCTTTGCC AAAAGTTCA ACAATTTGT AGACGCTAGA GATTATGTAA  
>.....*purD*.....>

1201 AAGAGCTCAC GCAATTCCCT ATCGTGATCA AAGCCAGTGG CTTGGCAGCA GGAAAGGTG TGATCATCGT GCACNTACAA  
>.....*purD*.....>

1281 CTTGAAGCCG AAACTACTTT GCGCAAAATC ATGGAAGACA AAACCTTGG CGAAGCAGGC AACGAGGTG TAATCGAGGA  
>.....*purD*.....>

1361 ATACTTAAA GGTGTGGAAG TTTCTGTGCT TTCTATCTTT AACCATAAG AAATTTAAAC TTTCTTGCT GTAAAAGACC  
>.....*purD*.....>

1441 ACAAGAAAAT CGGAAAAGGC GAAACAGGGAC TCAACACGGG CGGAATGGGC GTAGTGGCTC CTAACCCGCA TTTTACCGAT  
>.....*purD*.....>

1521 GAGCACATGA AGGAGTTGA GAAAAACATT TTGCTCCCAA CACAAAAGG GCTCTGGCA GAAAAAAATGC ATTTGCAGG  
>.....*purD*.....>

1601 CATTATTTTC TTTGGGCTTA TGATTACCGA GCATGGTATT TATCTATGGA AATACAACAT GCGATTTGGC GACCCAGAAA  
>.....*purD*.....>

1681 CCGAAGCACT TTTGCCTTG ATGGAGAATG ATTTAGTAGC CCTCATCGAT TCCGCAATAC ACCAGCAAGA CATTGAACCT  
>.....*purD*.....>

1761 AAATGGAAAA ACGAACATGC TTGCTGTGTA GTAATGGCGA GCGGTGGCTA CCCAGGCAGT TACGAAACTG GTTTGAAAT  
>.....*purD*.....>

1841 CCGAGGATTG AACAAAGTTG ATGTTCCGT ATTTATTGCA GGAGCCAGAG AAGAAAGTGG AAAATCTAC ACCACAGGCG  
>.....  
.....purD.....>

1921 GGCAGCTGCT CAATGTGGTG GGAAGCTGGCG CTACGCTAGA AGAAGCCAGA AAAGTGGCTT ACGAAAATAT CCATAAAATC  
>.....  
.....purD.....>  
.....  
.....>

BglIII

2001 AATTTGATT ATGAATATTA TCGCGAAGAC ATCGGAAGA TATAATCTCG CTGATTTA ACCAAAACAT ATTTAAAAAC  
>.....  
.....purD.....>>

2081 GCTTTGTTA CTTTATAAA CAAAGGGT TTTCTATTT TGTCGCACTA TAACATGATT TAACCCATGA AAAAAAATCT

2161 AAAAAACTC ATTTTCTAC TGTCATTCC TTGGGTTAT GCCCTGATTT TAATCTTTAT AAATCCACCT ATCACCATT

2241 CACAGCTGAG CAATTTATCT TATGGTTCT CCAGAACACA GCTCGCTTAT GATGAAATTC CGGCTAGTGC TAAATGGCT

2321 GTAATTGCAG CAGAAGACCA GAATTTGCC ATTCTAAATG GCTTGATTT TAAAGAAATT AAAACCGCCT ACGAGAAAAA

2401 CAAAGCGGGC AAGAAATTGC GTGGCGGGAG CACCCTTCG CAACAAACTG CAAAAAATGT ATTTTGTGG CAAGGGCGCA

2481 CTTGGATTAG AAAAGGATTG GAAACCTACT GCACCTTAT CATCGAAACG CTGTGGAGCA AGGAGCGTAT TTTGCAAGTT

2561 TACCTCAACA ATGCCAAAT GGGCAAAGGC GTTTATGGCA TAGAGGCAGC GGCGCAATAT TATTTAAGA AAAACGCCTC

2641 ACAGCTCACG CCTACCGAGA CGGCACGCAT CATTGCCCTGC CTGCCCAATC CAAAAAATA CAATNTAAAC CGGCCAAGTG

2721 CCTACATCTC AAAACGCGGA CAATGGATTG TGCGCCAAGT GCGAAACTTG AAAGGCGATA GGGCTCTGAG CGAGATTGTG

2801 AACACGCCCT AACGCCTGCC TCAACTCTT GCACACAGTT TACCAACTCT CTGCAGAGAG TTCACAAACT CTCGCACAC

2881 ACTTCCCCAA GTCTTTGCAA AGAGTGGGA GATACTTAGG CACAAAAAAA AGAACCTCA TGAATAGAGG TTCCCTCTTC

2961 CTTAAAGGA ATAAATAATA ATGTTTTA AGCTTAGGC TTGGCTACTT TTCAAGGC TGCTGCCCTC ATGCTATCTA  
.....

HindIII

3041 GGATACGCTT GCCTGGCGGG TAGTTACGC CTACCTTTT GATTAAGCCC GAATGAAAT CTTCTCTGT ATCTGCCGCT  
<<.....R8.....<

3121 CCACTGCTTA AAGTGGCATA GAGCGAGCCA AGCTTATCTA AACGAACGAT TTTGCCGCT GCCAAGCGT CTTGAATTAC  
<R8.<<AAGCTTAAG

HindIII

HindIII

3201 ATTCTCTAGC GCAATGATAA CGCCACGAAT ATCTGCCCTG CTGAGTGGCG AAAACTCTC GATTTGCTTA ACGAGCTGGT

3281 CTATATCCAT TTCTCCATCG CTTGCCACCA CGGCATAGTA TTTTGTTGGC TCCCCTGGCT TGCTTGGTT TCTACGCTGA

3361 ATTACATTGT ATTTTATGCT CATAATTACT CTATTTTAA TAGCCTCCCG ATGGATATAA AGTACGCTA CAATTAGGGT

3441 CTCCATAAGC AAATCTATAC CCCTCTCTT CATATCCCT TCTCATTCTT CTTGCTCCAT CTCTCAAGGC ATCCGCTCTA

3521 TTACTGCTAT ACCCCTCTG AAGAAATGTG TCTGCACTTG AAGAAGAATA TGAAGAGCTA TGAGAATCGT-GCAACATAGT

3601 CCAAGCTCCA TCTTGAGCTA TAACATTGC ATGACATGTA ACACCTATAG TATAATAAAA TCTCCTAGGA GTTGTGTT

3681 CACCAACCAC TCCAGAGCTA CTACTTTTT TACATTGTCC ATTTTGGTTA GCATGATTT GTCCGCCATC ACTTACTAAC

3761 TTCTTAGCTT CTGCTAAGGC TTTTCTCTT GCTTCTTTT CAGCATCTGC TTGGCTAATT CCACTCACTG CTGTAGCTGT

3841 CGCTTCTTT TTATAGTTA CCGAGGTTCC ATAATAGCCA CTACTACAAT TGTTCTGT AAAGTTTTA TTAAAAGATT

3921 GAGTTGTGT TGAGGTGTAC CCTCCGAAAC CTTTACTTC TACAGTAAAG GTAGAACTCC CCATGCTTAC GGGGAAGGTG

4001 GCGATAGTAT ACGATTGCC CTCGGCATT TGTTTACTT GATACACTCC ATCTCTCTT ACTTCTATGC TTGCCGTTAA

---

4081 ATTACCACTA CCGCTAAAAG AGCCTCTGC TATTTTTAGT GTTAAATCAT TTATATCCCC TCCTTGTCCCT TTTGCAGAAG  
4161 CTTTTGTTAC ACTTACAGCA TCATAAGCTC CTTTTCCATT GGTATAAGGT ATTTATATGG CCAAAC

---

Figure 2B.

1 TAAAGCTGTA AWTCGCTATA AACGCCCTT AGGATAAAAAT CTGCCATT TTGCAGTATT TTWATAGCTA AAATTTAGAA  
>.....FrecAO1.....>

81 AACACCATCT CGAGTAAAGG AGCGTGTAGT GCTGCCATC GTTGAGCGAT TGCCCACCCCT CAATTGATTT GGGCGAATAC  
CTTAAGCTT>.....F6.....>

-----  
*HindIII*

161 TTGAAATAAA TGGCATCTTC TAGCGACACA TTTTGCAG AAAATCATGCA AAAAGCCCCG CATAAAAAGC TGAATAAAAAA  
241 WGCTAWTYTT CTTGTTAAA AAAACTCATA AATTCCCCA AATATAGAAA TATTCTGTGA AAAGTTGCAA TTTATTAACA  
<<...<

321 CTATGTGCTT GCTTTAATG AAAAAAGTAG ATTATTTTC CGAATCCGAA AGTTTATTAA CGCCCCATCC GATGCCTAGT  
<..FrecA-4...<

401 CCCMSCGATA GCCATGATTA ATACAAATAC AATTAATCA WATTTTCMC MTWWACCATA GCACAACACT TGCTAGCTCA  
481 ACGAGTACTA GAGTGGTAA AAGGATTTT TGACGATTAT TCATGATTT ATTTCCTCA AAGGTAATAA TTTAAACCA  
561 TAATTCACA AATCTTTAAA TCTATTTAAA TAATAGAGAA ACCAGAAAAA AATCGTATTT TTACGGAATG AATAAAATGT  
641 TACAAGTAGG CGATAAAATG CCCGATTCA AAGGTGTTAGA CCAATTGGG AAGGAGGATT CATCTGCCGA TTCAAAAAT  
721 CAGAAATTAG TCGTTTTTT CTACCCAAA GCCAGTACGC CAGGTTGCAC GGCAGAGGCT TGCAACATCA ACGATAATCT  
801 TGATGCGCTA AAAGCACAAG GCTACCAAGT GATAGGGCGT AGTGCAGATT CGGTAGAAAA ACAACGAAAA TTCAGTGATA  
881 AATACGATT TAAATCCCT GTGATTGCCG ATGTGGATAA GAAAATTATT GAAGCATTG GCGTGTGGGG CGAAAAGAAA  
961 TTCATGGGTA AAACCTATGA CGGAATTCA CGTACGACAT TCATTATTGA TGAAAACGGA GTGGTGGAGC GCGTGATAGA  
>.....F7.....>

-----  
*EcoRI*

1041 AAAAGTAAA ACAAAAGATC ATACCAATCA AATTTAAAT TCAGAAAAAT AAAATATGA GCGAAATAGA CGAAGCGAAA  
>.....recA.....>

1121 AGGAAAGCAC TCCAGCTAGT GCTTGATAAA ATGGACAAAAA GCTATGGTAA AGGTGCCGTG ATGATGATGG GCGACAAAGC  
>.....recA.....>  
<<.....OER1.....<

1201 CATAGACGAA AATATTCCAG TAATCCCTAC GGGGTCTCTA GGTAGATT TAGCCTGGG CGTGGGAGGG TATCCGCGCG  
>.....recA.....>  
<CGAGATCTCGTGCCTGCGGT

-----  
*BglII*

1281 GTAGAATCGT GGAGATTTAC GGTCCAGAAT CTTCTGGTAA AACCACTTTG GCAATTCAATG CCATTGCCGA AGCTAAAAG  
>.....recA.....>

1361 TCTGGCGGAA TTGCAGCTTT CATCGATGCA GAGCACGCA TTGATAGATA TTACGAGAA AAATTAGGCG TAGATGTTGA  
>.....recA.....>

1441 GCATTTAATT ATCTCTCAGC CAGATAATGG GGAGCAAGCT TTAGAAATTG CCGATAACTT AATCCGTTCA GGTGCAATTG  
>.....recA.....>

-----  
*HindIII*

1521 ATATTATTGT AATCGATTG GTAGCGGCTT TAACGCCAAA GTCGGAAATC GACGGAGATA TGGGCGATTG CAAAATGGGA  
>.....recA.....>

1601 TTGCAAGCGC GTTTGATGTC TCAAGCCTTG AGAAAGCTCA CGGAACTAT CAATAAAACC AAATGTACTG CTATTTCAT  
>.....recA.....>

1681 CAACCAATTG AGAGAGAAAA TCGGTGTGAT GTTCGGTAGT CCAGAAACCA CAACGGTGG TAATGCACCTT AAATTCTATG  
>.....recA.....>

1761 CATCGGTGCG TCTAGACATT CGTCGTTCTA CTCAGATTAA AGATGGAAC GATGTCATCG GAAACTTGAC TCGCGTAAAA  
>.....recA.....>

1841 GTAGTGAAGA ACAAAAGTAGC TCCGCCATTC CGTAGTGCAG AATTGCACAT TATGTATGGC GAAGGAATCT CTAAAGCAGG  
>.....recA.....>

EcoRI

1921 CGAGATTTA GACATTGCTA CCGATTAGA AATCGTAAAA AAAAGTGGCT CTTGGTATTCTT ATGCAGAT ACTAAACTAG  
>.....recA.....>

2001 GACAAGGGCG AGATGCCGTG CGTGCAGGTAT TGAAAGATAA TCCAGAATTA GCCGAAGAAT TAGAAGAGAA AATTAAGAA  
>.....recA.....>  
CGAGATCT>>.....OEF1.....>>

BglII

2081 GAATTAGAGA AAAAATAGAT TTTTAGTTT TTTAATTAA ACGAAAATC CGTTCACTTT GTGAAACGGA TTTTTTATG  
>.....recA.....>>

2161 CTTGAATGAA TTTATTTCCA ATGGATTGAA TAGCCATGCA CTTTAAATC TTGCTATCA TAAGTGTATT CTTTGTGGT

2241 GTGGGATAG CAAACTTAA GTCCCTGCGTA TTTGGCAATG GCATGTCCTG CGGCAATGTC CCAAAAGTTT ACAGGTCTAA

2321 AGCGGGTGTGTA CTCCGTAGCC CACCGATCGG CAATTAGCCC AAGTTGATA ACGCTTCCCA TAGGCTTTGT GCGGAAAATT

2401 TCATGTCGG ATTTAATTTC TTGATGTAT TCCTCGGTGC CAGGATCCAT GTGGAATTG CTACAAAGAA AAGTGTAAATC

2481 TTCGGGCAAA TCCATGGTAG GAATTGGCTT GCTGTGTTTC ATCAATTGTT CAAAAAAATC CGATTTCAGA GCCATTTGT

2561 GCAATTGTTG TTGAGTCCCG ATGAATTAC GAGAAGGGCA TTTATCGCTA CCGAAATAGA ACAATCCAAG CGATGGGCG

2641 TACAAAATC CTAGCTTAGC CGTATTATTC TCAACTAAGC CTAGACACAC GCAATATTCA TCTGTTTGT TGACAAAATC

2721 CATGGTGCCA TCAATAGGGT CTGCAATCCA ATAGGGGGC GTATTCTAA TTCTTGAA AGAATCCTTA TCTCCTTCCT

2801 CACTAAAGTA TGGAAATGTCT GTAAAGGAAA CATGTTTTG CAAGATTTG TTGGGGCTA AATCTGCCT TGTAACAGGC

2881 GATCCGTCGG CTTTGGTCTC GGTGGAGAAT CCGTTTGGG TTGTTTAAA ACCTCTCGC CAGCAAGTGC TACAGCCCGT

2961 GTTGCAGATT CTAATAAATT CATAATCATT CTTTATTCT CGAACAAAGT CAAATAATTC TCTGTTTAA AAAATAATTT

3041 TGGCGATAAA AATTAAAATT TATATATAAA ATATCTCTGC AAAAAACCAA ATCAAATATT TAGTGAATAA AAAAAAATTA

3121 GATTGTAAAT TTGCCTTATG TTTTAGAGA ATACCATAAA TCATAGAAAA AATACGGGCT GGATCGAAGT AATCTGTGGC

3201 TCTATGTTT CGGGCAAAAC CGAAGAGTTG ATTCTGAGAG TGAAACGAGC CGAATTGGCT GGGCAAAAGG TAGAAATCTT  
<<.....R5.....<<AAGCTTAAG

HindIII

3281 TAAACCCGCA ATTGATAAAC GCTACGATGA GCAAGATGTG GTATGCCATG ATGAAAACAA AAAACAAGCA ACCCCGATTG

3361 AGGCAGTTTC TAACTTGCCC ATTTAGCAA GCGATTGTGA TGTGGGGGG ATAGATGAGG CTCAATTCTT TGACGAAGGA

3441 ATTGTTGAGG TGGCAAATCT TTTAGCTAAT TCGGGGAAAA GAATAATTAT TGCGGGATTA GACATGGATT TTAAAGGTGC  
<<.....RrecAOR1.....<<

3521 TCCATTTGGT CCTATGCCA ATTAATGGC GGTAGCGGAA TATGTGACCA AAGTGCATGC AATCTGTGTG AAAACAGGGA

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP04/053623

International filing date: 21 December 2004 (21.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: EP  
Number: 03104954.7  
Filing date: 23 December 2003 (23.12.2003)

Date of receipt at the International Bureau: 04 February 2005 (04.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**